[1]龚显田,陈丽梅,李子才,等.瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛临床研究[J].陕西中医,2021,(7):886-889.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.019]
　GONG Xiantian,CHEN Limei,LI Zicai,et al.Clinical Study on Gualou Xiebai Banxia decoction and Shixiao powder modified in treating coronary heart disease angina pectoris[J].,2021,(7):886-889.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.019]
点击复制

瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年7期
页码:
886-889
栏目:
临床研究
出版日期:
2021-07-09

文章信息/Info

Title:
Clinical Study on Gualou Xiebai Banxia decoction and Shixiao powder modified in treating coronary heart disease angina pectoris
作者:
龚显田; 陈丽梅; 李子才; 何周欢
(眉山市中医医院内二科,四川 眉山620010)
Author(s):
GONG Xiantian; CHEN Limei; LI Zicai; HE Zhouhuan
(Meishan Hospital of Traditional Chinese Medicine,Meishan 620010,China)
关键词:
冠心病;  心绞痛;  瓜蒌薤白半夏汤;  失笑散;  心功能;  血脂水平;  抗氧化
Keywords:
Coronary heart disease;  Angina pectoris;  Gualou Xiebai Banxia decoction;  Shixiao powder;  Cardiac function;  Blood lipids levels;  Antioxidant
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.07.019
文献标志码:
A
摘要:
目的:探讨瓜蒌薤白半夏汤合失笑散加减治疗对冠心病心绞痛患者心功能、血脂水平及抗氧化指标的影响研究。方法:将冠心病心绞痛患者70例随机分为对照组和观察组各35例,对照组患者给予常规药物治疗,观察组在此基础上,加用瓜蒌薤白半夏汤合失笑散加减治疗。比较两组患者治疗后临床疗效、中医症候积分、心功能指标、血脂水平及抗氧化指标变化。结果:治疗后,观察组患者总有效率(94.29%)显著高于对照组(74.29%)(P<0.05); 两组患者中医症候积分均较治疗前显著降低(P<0.05),两组比较差异有统计学意义(P<0.05); 两组患者心功能指标LVEF、CI、CO及SV均较治疗前显著升高(P<0.05),两组比较差异有统计学意义(P<0.05); 两组患者TC、TG及LDL-C水平均较治疗前显著降低(P<0.05),HDL-C水平较治疗前显著升高(P<0.05),两组比较差异均有统计学意义(P<0.05); 两组患者指标SOD、CAT及GSH-Px均较治疗前显著升高(P<0.05),指标LPO较治疗前显著降低(P<0.05),且观察组与对照组比较差异均有统计学意义(P<0.05)。结论:瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛患者临床疗效显著,可有效提高患者心功能,改善血脂水平及抗氧化指标。
Abstract:
Objective:To explore the effect of modified Gualou Xiebai Banxia decoction with Shixiao powder on cardiac function,blood lipids levels and antioxidant indicators in patients with coronary heart disease complicated with angina pectoris.Methods:70 patients with coronary heart disease complicated with angina pectoriswere were randomly divided into control group and observation group,with 35 cases in each group.Control group received conventional medicine treatment,and observation group was additionally treated with modified Gualou Xiebai Banxia decoction with Shixiao powder on this basis.The clinical efficacy,TCM symptoms scores,cardiac function indexes,blood lipids levels and antioxidant indicators were compared between the two groups of patients after treatment.Results:After treatment,the total effective rate of observation group was significantly higher than that in control group(P<0.05).The scores of TCM symptoms in the two groups were significantly decreased compared with those before treatment(P<0.05),and the observation group were significantly different from those in control group(P<0.05).The cardiac function indexes of LVEF,CI,CO and SV of the two groups were significantly increased compared with those before treatment(P<0.05),and the observation group were significantly different from those of control group(P<0.05).The levels of TC,TG and LDL-C in the two groups were significantly decreased compared with those before treatment(P<0.05).While the level of HDL-C was significantly increased compared with that before treatment(P<0.05),and observation group were significantly different from those in control group(P<0.05).The levels of SOD,CAT and GSH- Px in the two groups were significantly increased compared with those before treatment(P<0.05).While the level of LPO was significantly decreased compared with that before treatment(P<0.05),and there were significant differences between observation group and control group(P<0.05).Conclusion: Modified Gualou Xiebai Banxia decoction with Shixiao powder has a significant clinical effect in the treatment of patients with coronary heart disease complicated with angina pectoris,and it can effectively enhance the cardiac function,and improve blood lipids levels and antioxidant indicators.

参考文献/References:

[1] 石衍梅,李 洁,蔚若川,等.冠心病发病机制研究进展[J].中国冶金工业医学杂志,2016,33(2):137-138.
[2] 毕颖斐,王贤良,毛静远,等.基于临床流行病学调查的冠心病心绞痛中医证候诊断建议[J].中医杂志,2018,59(22):1977-1980.
[3] 黄壮壮,聂西洲,陈衍斌,等.冠心病医学认识及相关药物治疗概况[J].陕西中医,2017,38(1):135-136.
[4] 李艳娟,王凤荣,张明雪,等.冠心病心绞痛中医证候的文献研究[J].世界中医药,2016,11(3):558-564.
[5] 冯小智,刁 杰,方 婷,等.中医辨证治疗对行介入疗法的急性心肌梗死患者心肌再灌注和心功能的改善作用[J].中华中医药学刊,2018,36(11):2760-2763.
[6] 薛慧文,李建锋,傅旎旎,等.瓜蒌薤白半夏汤不同提取部位对心肌细胞保护作用比较研究[J].药物评价研究,2018,41(1):67-72.
[7] 贾鸿扬,徐 英.张大宁教授应用茵陈失笑散治疗慢性肾功能衰竭验案[J].西部中医药,2016,29(3):68-70.
[8] 梁茂新,高天舒.《中药新药临床研究指导原则》脏腑诸证考察与分析[J].中国中医基础医学杂志,2008,14(5):330-331,342.
[9] 柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304.
[10] 国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:126-128.
[11] 沈 琳,马文苑.曲美他嗪联合氯吡格雷治疗冠心病心绞痛疗效及对患者心电图、血清超敏C反应蛋白和五聚素3的影响[J].陕西医学杂志,2019,48(6):794-796.
[12] 王婧文,孔维颖,白云浩,等.冠心病合并2型糖尿病与单纯冠心病发病机制及危险因素分析[J].中西医结合心脑血管病杂志,2017,15(23):2999-3002.
[13] 魏 群,魏 明.中西医结合治疗冠心病心绞痛的临床研究[J].中国中医基础医学杂志,2015,21(12):1530-1532.
[14] 龙 娜,刘淑霞.胸痹心痛的中医研究进展[J].陕西中医,2015,36(2):253-254.
[15] 张 玉.冠心病胸痹发病相关因素与五脏关系初探[D].北京:北京中医药大学,2016.
[16] 许剑婕,仇 军,张广宏,等.瓜蒌薤白半夏汤结合血府逐瘀汤治疗冠心病心绞痛的临床分析[J].中西医结合心脑血管病杂志,2017,15(18):2277-2280.
[17] 敖 勇,罗 杨,杨 建,等.丹参注射液对冠心病患者血清LPO、SOD、NO及MDA的影响[J].中国生化药物杂志,2016,36(1):139-140.
[18] 吴 滨,刘 亮,杨 琳.针灸联合血府逐瘀汤对不稳定型心绞痛患者临床症状、血清过氧化氢酶水平及心率变异性影响[J].辽宁中医药大学学报,2020,22(3):180-184.
[19] 马春静,谢 维,刘春旺.老年糖尿病合并冠心病患者血清同型半胱氨酸、MCP-1、血尿酸与冠状动脉病变相关性分析[J].中外医疗,2019,38(8):185-187.
[20] 张洪兵,李七一.冠心平片对冠心病心绞痛患者抗氧化酶及炎症因子的影响[J].中成药,2017,39(7):1545-1547.

相似文献/References:

[1]朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM1〖JZ〗及ICAM1影响的研究*[J].陕西中医,2019,(3):290.
　ZHU Wei..Effect of Tongmai Tiaozhi recipe on the efficacy, Hemorheology, VCAM1 and ICAM1 〖JZ〗in patients with stable angina pectoris of coronary heart disease[J].,2019,(7):290.
[2]时晓华.丹参多酚酸盐注射液辅助介入治疗冠心病 及对患者心、肾功能和心肌损伤的影响*[J].陕西中医,2019,(5):568.
　SHI Xiaohua..Effects of salvianolate injection on cardiac function, renal function, myocardial injury in percutaneous coronary intervention postoperative patients with coronary heart disease[J].,2019,(7):568.
[3]刘 红,张玲燕,杨 玲.血府逐瘀汤治疗冠心病介入术后心绞痛临床研究[J].陕西中医,2019,(5):594.
　LIU Hong,ZHANG Lingyan,YANG Ling..Clinical observation of Xuefu Zhuyu decoction in the treatment of angina pectoris after PCI for coronary heart disease[J].,2019,(7):594.
[4]吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响*[J].陕西中医,2019,(6):714.
　LV Yongfei,CHEN Ailian..Effect of Yixin Kangtai capsule on the curative effect hemorheology and vascular endothelial function after coronary artery disease PCI[J].,2019,(7):714.
[5]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(7):854.
[6]解洪涛,张 顺△,曾广伟.当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*[J].陕西中医,2019,(10):1341.
　XIE Hongtao,ZHANG Shun,ZENG Guangwei..Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting[J].,2019,(7):1341.
[7]索晓菲,王亚红△,王居新,等.软坚通脉汤治疗冠心病PCI术后Ⅱ期心脏康复疗效〖JZ〗及对患者生活质量的影响*[J].陕西中医,2020,(1):29.
[8]尹 毅,李小兰△.益气活血汤联合尼可地尔治疗稳定性心绞痛疗效及对患者T淋巴细胞亚群的影响[J].陕西中医,2020,(7):888.[doi:DOI:10.3969/j.issn.10007369.2020.07.014]
[9]季学清,刘 萍△,陈宝瑾,等.冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*[J].陕西中医,2020,(9):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
　JI Xueqing,LIU Ping,CHEN Baojin,et al.Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu[J].,2020,(7):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
[10]肖 进,张新莉.醒脾祛湿汤治疗湿浊痹阻型胸痹心痛临床研究[J].陕西中医,2021,(4):463.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.015]
　XIAO Jin,ZHANG Xinli.Clinical study on chest pain patients with Shizhuo Bizu type treated by Xingpi Qushi decoction[J].,2021,(7):463.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.015]
[11]汪思慧,沈 雁.从“络以辛为泄”论治冠心病心绞痛研究进展[J].陕西中医,2022,(12):1822.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.043]
[12]曾建勇,王小玲,范小虹,等.复方丹参滴丸联合阿托伐他汀治疗冠心病合并心绞痛疗效及对患者氧化应激指标的影响[J].陕西中医,2023,(1):55.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.013]
　ZENG Jianyong,WANG Xiaoling,FAN Xiaohong,et al.Efficacy of compound Danshen dripping pills combined with atorvastatin in the treatment of coronary heart disease with angina pectoris and its influence on oxidative stress indicators of patients[J].,2023,(7):55.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.013]

备注/Memo

备注/Memo:
基金项目:四川省眉山市科技局基金资助项目(2019KJZD14)
更新日期/Last Update: 2021-07-07